American Fusion Inc. (OTC: AMFN) provided an update after Chief Technology Officer Dr. John Brandenburg presented the company’s Texatron Fusion Engine platform at the IEEE International Conference on Plasma Science (“ICOPS”) 2026 on June 22. Management reported strong engagement from researchers and industry professionals attending the conference, with extensive follow-up discussions surrounding the company’s compact fusion technology and its potential role in future energy production.
American Fusion said it is advancing discussions with Texas Tech University, Dr. Robert Duncan and Blankslate Innovation regarding potential use of a specialized testing facility in Lubbock, Texas, which management believes could accelerate validation efforts and expand scientific capabilities. The company also recently transported its 5MW pre-production Texatron Fusion Engine to the Fort Worth area for installation and commissioning and is evaluating deployment of advanced FT-ICR mass spectrometry technology to enhance plasma diagnostics, isotopic analysis and system performance validation as it moves toward technical and commercial milestones.
The presentation at ICOPS 2026 marks a significant step for American Fusion as it seeks to validate its technology within the scientific community. The company’s neutronic fusion platform is designed for modular, infrastructure-grade deployment across industrial, commercial, and grid-constrained applications. By engaging with researchers and industry professionals, American Fusion aims to build credibility and foster collaborations that could accelerate the path to commercialization.
The discussions with Texas Tech University and other partners highlight the company’s strategy to leverage existing facilities and expertise. The specialized testing facility in Lubbock could provide the necessary environment for rigorous validation of the Texatron Fusion Engine, potentially reducing development time and costs. Additionally, the transport of the 5MW pre-production unit to the Fort Worth area for installation and commissioning indicates progress toward operational testing.
American Fusion’s evaluation of advanced FT-ICR mass spectrometry technology underscores its commitment to enhancing plasma diagnostics and system performance. This technology could enable more precise isotopic analysis and validation, which are critical for demonstrating the efficiency and reliability of the fusion engine. As the company moves toward technical and commercial milestones, these advancements could position it as a key player in the fusion energy sector.
For more information, visit the company’s newsroom at http://nnw.fm/AMFN.
